Safety and pharmacokinetics study of adalimumab with Halozyme's proprietary ENHANZE technology
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2016
At a glance
- Drugs Adalimumab (Primary) ; Hyaluronidase
- Indications Immunological disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 21 Nov 2016 According to a Halozyme Therapeutics, Inc media release, AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of this study in which the target results were not achieved.
- 21 Nov 2016 Status changed from recruiting to completed, as per a Halozyme Therapeutics media release.
- 25 Jan 2016 New trial record